基于MRI斑块易损性的症状性颈动脉病个体化卒中预测评分(IMPROVE)
IMPROVE模型基于5个队列760例接受最佳药物治疗的症状性颈动脉病患者,纳入斑块内出血、狭窄程度等5个预测因子,用于估算3年同侧缺血性卒中风险。内部验证C统计量0.82,校准斜率0.93,高危分层灵敏度92.6%优于常规诊疗的80.6%,但需外部验证。
要点
- IMPROVE模型含5个预测因子:狭窄程度、斑块内出血、末次事件分类、男性、年龄。
- 内部验证C统计量0.82(95%CI 0.77-0.87),校准斜率0.93。
- IMPROVE高危cutoff灵敏度92.6% vs 常规诊疗80.6%,特异性54.2% vs 52.9%。
核心结论
- IMPROVE模型利用MRI斑块内出血和4个常规参数,可提供准确的个体化卒中风险估计,可能有助于血运重建分层,但需外部验证。
研究设计与样本
- IMPROVE基于5个队列760例接受最佳药物治疗的症状性颈动脉病患者数据开发,纳入近期TIA/卒中(<6个月)、有MRI斑块内出血信息、无房颤且未立即血运重建者。
- 采用Cox回归,使用5个专家选择的预测因子,内部验证后转换为3年同侧缺血性卒中风险。
- IMPROVE高危定义为≥中位3年IMPROVE风险,常规诊疗高危定义为颈动脉狭窄≥50%。
主要发现
- IMPROVE模型5个预测因子 hazard ratio(95%CI):狭窄程度(<50%为参照,50%-69%:4.54 [2.46-8.38],70%-99%:7.42 [3.45-15.95])、斑块内出血(5.61 [2.92-10.77])、末次事件分类(眼部为参照,脑部:3.72 [1.11-12.52])、男性(1.26 [0.64-2.48])、年龄(每增加10岁:1.14 [0.84-1.55])。
- 内部验证C统计量0.82(95%CI 0.77-0.87),校准斜率0.93。
- IMPROVE高危cutoff灵敏度92.6%(90.7-94.5)vs 常规诊疗80.6%(77.8-83.4);特异性IMPROVE 54.2%(50.7-57.8)vs 常规诊疗52.9%(49.3-56.4)。
- IMPROVE高危患者同侧缺血性卒中发生率24.0%,常规诊疗高危分类为20.7%;IMPROVE和常规诊疗低危患者中分别有2.1%和5.3%发生同侧缺血性卒中。
关键数值与推荐
- IMPROVE高危:≥中位3年IMPROVE风险;常规诊疗高危:颈动脉狭窄≥50%。
- IMPROVE模型预测因子:狭窄程度、斑块内出血、末次事件分类、男性、年龄。
临床怎么用
- IMPROVE模型可能有助于症状性颈动脉病患者血运重建分层,但需外部验证。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In symptomatic carotid stenosis, treatment decisions are currently primarily based on stenosis degree. We developed a clinical prediction model (Individualized Magnetic Resonance Imaging-Based Stroke Prediction Score Using Plaque Vulnerability for Patients With Symptomatic Carotid Artery Disease [IMPROVE]) incorporating the strong predictor, intraplaque hemorrhage on magnetic resonance imaging, stenosis degree, and risk factors to identify patients with high stroke risk. METHODS: IMPROVE was developed on data from 5 cohorts of 760 patients with symptomatic carotid disease on optimal medical treatment. Inclusion criteria included a recent transient ischemic attack/stroke (<6 months), magnetic resonance imaging-based information on intraplaque hemorrhage, no atrial fibrillation, and no immediate revascularization. IMPROVE was based on Cox regression using 5 expert-selected predictors and converted to 3-year ipsilateral ischemic stroke risk after internal validation. IMPROVE-based stratification was compared with care-as-usual using illustrative cutoffs: high risk was defined in IMPROVE as ≥ median 3-year IMPROVE risk, whereas in care-as-usual, it was ≥50% carotid stenosis. RESULTS: Sixty-five ipsilateral ischemic strokes occurred during a median follow-up of 1.2 years (interquartile range, 0.5-4.1). The IMPROVE model includes 5 predictors (hazard ratio [95% CI]): degree of stenosis (<50%: reference, 50%-69%: 4.54 [2.46-8.38], 70%-99% stenosis: 7.42 [3.45-15.95]), presence of intraplaque hemorrhage (5.61 [2.92-10.77]), classification of last event (ocular: reference, cerebral: 3.72 [1.11-12.52]), male sex (1.26 [0.64-2.48]), and age (1.14 [0.84-1.55] per 10-year increase). Internal validation revealed good accuracy (C statistic, 0.82 [95% CI, 0.77-0.87]) and no evidence of miscalibration (calibration slope, 0.93). Sensitivity for the illustrative IMPROVE cutoff was 92.6% (90.7-94.5) versus 80.6% (77.8-83.4) for care-as-usual. Specificity was 54.2% (50.7-57.8) for IMPROVE versus 52.9% (49.3-56.4) for care-as-usual. Patients stratified by IMPROVE as high risk had a higher incidence of ipsilateral ischemic stroke (24.0%) compared with the care-as-usual classification (20.7%). Among patients classified as lower-risk by IMPROVE and care-as-usual, 2.1% and 5.3%, respectively, experienced an ipsilateral ischemic stroke during follow-up. CONCLUSIONS: Using the presence of intraplaque hemorrhage on magnetic resonance imaging and 4 conventional parameters, the IMPROVE model provides accurate individual stroke risk estimates, which may facilitate stratification for revascularization after external validation.
引用
- Nies KPH, Smits LJM, van Kuijk SMJ, et al. Individualized MRI-Based Stroke Prediction Score Using Plaque Vulnerability for Symptomatic Carotid Artery Disease Patients (IMPROVE). Stroke. 2025. PMID: 40336502. doi:10.1161/STROKEAHA.124.050020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。